Cartilage-specific deletion of Mig-6 results in osteoarthritis-like disorder with excessive articular chondrocyte proliferation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 7, 2014, Pages 2590-2595

  Staal, Ben ^a   Williams, Bart O ^a   Beier, Frank ^b   Woude, George F Vande ^a   Zhang, Yu Wen ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

EGFR; Errfi1; Gene 33; RALT

Indexed keywords

BETA GALACTOSIDASE; COLLAGEN TYPE 10; COLLAGEN TYPE 2; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEOGLYCAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CELL PROLIFERATION; CONTROLLED STUDY; ENCHONDRAL OSSIFICATION; GENE DELETION; GENE EXPRESSION; HOMEOSTASIS; HOMOLOGOUS RECOMBINATION; IMMEDIATE EARLY GENE; JOINT; KNEE OSTEOARTHRITIS; MITOGEN INDUCIBLE GENE 6; MOUSE; MOUSE STRAIN; NONHUMAN; OSTEOARTHRITIS; OSTEOPHYTE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; SYNOVIUM; TRANSGENIC MOUSE;

EGFR; ERRFI1; GENE 33; RALT;

ANIMALS; BETA-GALACTOSIDASE; CARTILAGE, ARTICULAR; CELL PROLIFERATION; CHONDROCYTES; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; OSTEOARTHRITIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84894358274     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1400744111     Document Type: Article

References (35)

1. Zhang YW, Vande Woude GF (2007) Mig-6, signal transduction, stress response and cancer. Cell Cycle 6(5):507-513.
2. Zhang YW, Vande Woude GF (2013) MIG-6 and SPRY2 in the regulation of receptor tyrosine kinase signaling: Balancing act via negative feedback loops. Future Aspects of Tumor Suppressor Gene, ed Cheng Y (InTech, Rijeka, Croatia), pp 199-221.
3. Anastasi S, et al. (2003) Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene 22(27):4221-4234.
4. Zhang X, et al. (2007) Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450(7170):741-744.
5. Frosi Y, et al. (2010) A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation. J Cell Biol 189(3):557-571.
6. Hackel PO, Gishizky M, Ullrich A (2001) Mig-6 is a negative regulator of the epidermal growth factor receptor signal. Biol Chem 382(12):1649-1662.
7. Makkinje A, et al. (2000) Gene 33/Mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy. Possible role in the response to persistent stress. J Biol Chem 275(23):17838-17847.
8. Zhang YW, et al. (2007) Evidence that MIG-6 is a tumor-suppressor gene. Oncogene 26(2):269-276.
9. Ferby I, et al. (2006) Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med 12(5):568-573.
10. Jin N, et al. (2009) Mig-6 is required for appropriate lung development and to ensure normal adult lung homeostasis. Development 136(19):3347-3356.
11. Zhang YW, et al. (2005) Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease. Proc Natl Acad Sci USA 102(33):11740-11745.
12. Burton-Wurster N, et al. (2005) Genes in canine articular cartilage that respond to mechanical injury: Gene expression studies with Affymetrix canine GeneChip. J Hered 96(7):821-828.
13. Mateescu RG, Todhunter RJ, Lust G, Burton-Wurster N (2005) Increased MIG-6 mRNA transcripts in osteoarthritic cartilage. Biochem Biophys Res Commun 332(2):482-486.
14. Lawrence RC, et al.; National Arthritis Data Workgroup (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58(1):26-35.
15. Brandi ML, et al. (2001) Genetic markers of osteoarticular disorders: Facts and hopes. Arthritis Res 3(5):270-280.
16. van der Kraan PM (2012) Osteoarthritis year 2012 in review: Biology. Osteoarthritis Cartilage 20(12):1447-1450.
17. Loeser RF, Goldring SR, Scanzello CR, Goldring MB (2012) Osteoarthritis: A disease of the joint as an organ. Arthritis Rheum 64(6):1697-1707.
18. Buckwalter JA, Mankin HJ, Grodzinsky AJ (2005) Articular cartilage and osteoarthritis. Instr Course Lect 54:465-480.
19. Tchetina EV (2011) Developmental mechanisms in articular cartilage degradation in osteoarthritis. Arthritis (Egypt) 2011:683970.
20. Goldring MB (2000) The role of the chondrocyte in osteoarthritis. Arthritis Rheum 43(9):1916-1926.
21. Sakai K, et al. (2001) Stage-and tissue-specific expression of a Col2a1-Cre fusion gene in transgenic mice. Matrix Biol 19(8):761-767.
22. Farley FW, Soriano P, Steffen LS, Dymecki SM (2000) Widespread recombinase expression using FLPeR (flipper) mice. Genesis 28(3-4):106-110.
23. Schwenk F, Baron U, Rajewsky K (1995) A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res 23(24):5080-5081.
24. Kronenberg HM (2003) Developmental regulation of the growth plate. Nature 423(6937):332-336.
25. Karsenty G, Wagner EF (2002) Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2(4):389-406.
26. Altman R, et al.; Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 29(8):1039-1049.
27. Shepard JB, Jeong JW, Maihle NJ, O'Brien S, Dealy CN (2013) Transient anabolic effects accompany epidermal growth factor receptor signal activation in articular cartilage in vivo. Arthritis Res Ther 15(3):R60.
28. Schneider MR, Sibilia M, Erben RG (2009) The EGFR network in bone biology and pathology. Trends Endocrinol Metab 20(10):517-524.
29. Zhu J, Shimizu E, Zhang X, Partridge NC, Qin L (2011) EGFR signaling suppresses osteoblast differentiation and inhibits expression of master osteoblastic transcription factors Runx2 and Osterix. J Cell Biochem 112(7):1749-1760.
30. Usmani SE, et al. (2012) Transforming growth factor alpha controls the transition from hypertrophic cartilage to bone during endochondral bone growth. Bone 51(1): 131-141.
31. Zhang X, et al. (2011) The critical role of the epidermal growth factor receptor in endochondral ossification. J Bone Miner Res 26(11):2622-2633.
32. Hallbeck AL, Walz TM, Briheim K, Wasteson A (2005) TGF-alpha and ErbB2 production in synovial joint tissue: Increased expression in arthritic joints. Scand J Rheumatol 34(3):204-211.
33. Appleton CT, Usmani SE, Bernier SM, Aigner T, Beier F (2007) Transforming growth factor alpha suppression of articular chondrocyte phenotype and Sox9 expression in a rat model of osteoarthritis. Arthritis Rheum 56(11):3693-3705.
34. Appleton CT, Usmani SE, Mort JS, Beier F (2010) Rho/ROCK and MEK/ERK activation by transforming growth factor-alpha induces articular cartilage degradation. Lab Invest 90(1):20-30.
35. Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, Mulligan RC (1991) Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl protooncogene. Cell 65(7):1153-1163.